Microsoft word - 9090703.doc
Tablets, 1 mg
PROPECIA* (finasteride), a synthetic 4-azasteroid compound, is a specific inhibitor of steroid Type II
5α-reductase, an intracellular enzyme that converts the androgen testosterone into5α-dihydrotestosterone (DHT).
Finasteride is 4-azaandrost-1-ene-17-carboxamide,N-(1,1-dimethylethyl)-3-oxo-,(5α,17β)-. The
empirical formula of finasteride is C23H36N2O2 and its molecular weight is 372.55. Its structural formula is:
Finasteride is a white crystalline powder with a melting point near 250°C. It is freely soluble in
chloroform and in lower alcohol solvents but is practically insoluble in water.
PROPECIA tablets for oral administration are film-coated tablets that contain 1 mg of finasteride and
the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, pregelatinized starch,sodium starch glycolate, docusate sodium, magnesium stearate, hydroxypropyl methylcellulose 2910,hydroxypropyl cellulose, titanium dioxide, talc, yellow ferric oxide, and red ferric oxide.
Finasteride is a competitive and specific inhibitor of Type II 5α-reductase, an intracellular enzyme that
converts the androgen testosterone into DHT. Two distinct isozymes are found in mice, rats, monkeys,and humans: Type I and II. Each of these isozymes is differentially expressed in tissues anddevelopmental stages. In humans, Type I 5α-reductase is predominant in the sebaceous glands of mostregions of skin, including scalp, and liver. Type I 5α-reductase is responsible for approximately one-thirdof circulating DHT. The Type II 5α-reductase isozyme is primarily found in prostate, seminal vesicles,epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT.
In humans, the mechanism of action of finasteride is based on its preferential inhibition of the Type II
isozyme. Using native tissues (scalp and prostate), in vitro binding studies examining the potential offinasteride to inhibit either isozyme revealed a 100-fold selectivity for the human Type II 5α-reductase overType I isozyme (IC50=500 and 4.2 nM for Type I and II, respectively). For both isozymes, the inhibition byfinasteride is accompanied by reduction of the inhibitor to dihydrofinasteride and adduct formation withNADP+. The turnover for the enzyme complex is slow (t1/2 approximately 30 days for the Type II enzymecomplex and 14 days for the Type I complex).
Finasteride has no affinity for the androgen receptor and has no androgenic, antiandrogenic,
estrogenic, antiestrogenic, or progestational effects. Inhibition of Type II 5α-reductase blocks theperipheral conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT
* Registered trademark of MERCK & CO., INC.
COPYRIGHT MERCK & CO., INC., 1997All rights reserved.
concentrations. Finasteride produces a rapid reduction in serum DHT concentration, reaching 65%suppression within 24 hours of oral dosing with a 1-mg tablet.
In men with male pattern hair loss (androgenetic alopecia), the balding scalp contains miniaturized hair
follicles and increased amounts of DHT compared with hairy scalp. Administration of finasteridedecreases scalp and serum DHT concentrations in these men. The relative contributions of thesereductions to the treatment effect of finasteride have not been defined. By this mechanism, finasterideappears to interrupt a key factor in the development of androgenetic alopecia in those patients geneticallypredisposed.
Finasteride had no effect on circulating levels of cortisol, thyroid-stimulating hormone, or thyroxine, nor
did it affect the plasma lipid profile (e.g., total cholesterol, low-density lipoproteins, high-densitylipoproteins and triglycerides) or bone mineral density. In studies with finasteride, no clinically meaningfulchanges in luteinizing hormone (LH) or follicle-stimulating hormone (FSH) were detected. In healthyvolunteers, treatment with finasteride did not alter the response of LH and FSH to gonadotropin-releasinghormone, indicating that the hypothalamic-pituitary-testicular axis was not affected. Mean circulating levelsof testosterone and estradiol were increased by approximately 15% as compared to baseline, but theseremained within the physiologic range.
Following an oral dose of 14C-finasteride in man, a mean of 39% (range, 32-46%) of the dose was
excreted in the urine in the form of metabolites; 57% (range, 51-64%) was excreted in the feces. Themajor compound isolated from urine was the monocarboxylic acid metabolite; virtually no unchanged drugwas recovered. The t-butyl side chain monohydroxylated metabolite has been isolated from plasma.
These metabolites possessed no more than 20% of the 5α-reductase inhibitory activity of finasteride.
In a study in 15 healthy male subjects, the mean bioavailability of finasteride 1-mg tablets was 65%
(range 26-170%), based on the ratio of AUC relative to a 5-mg intravenous dose infused over 60 minutes.
Following intravenous infusion, mean plasma clearance was 165 mL/min (range, 70-279 mL/min) andmean steady-state volume of distribution was 76 liters (range, 44-96 liters). In a separate study, thebioavailability of finasteride was not affected by food.
Approximately 90% of circulating finasteride is bound to plasma proteins. Finasteride has been found
There is a slow accumulation phase for finasteride after multiple dosing. At steady state following
dosing with 1 mg/day, maximum finasteride plasma concentration averaged 9.2 ng/mL (range, 4.9-13.7 ng/mL) and was reached 1 to 2 hours postdose; AUC(0-24 hr) was 53 ng•hr/mL (range, 20-154 ng•hr/mL) and mean terminal half-life of elimination was 4.8 hours (range, 3.3-13.4 hours).
Semen levels have been measured in 35 men taking finasteride 1 mg daily for 6 weeks. In 60% (21 of
35) of the samples, finasteride levels were undetectable. The mean finasteride level was 0.26 ng/mL andthe highest level measured was 1.52 ng/mL. Using this highest semen level measured and assuming100% absorption from a 5-mL ejaculate per day, human exposure through vaginal absorption would be upto 7.6 ng per day, which is 750 times lower than the exposure from the no-effect dose for developmentalabnormalities in Rhesus monkeys (see PRECAUTIONS, Pregnancy).
The elimination rate of finasteride decreases somewhat with age. Mean terminal half-life is
approximately 5-6 hours in men 18-60 years of age and 8 hours in men more than 70 years of age. Thesefindings are of no clinical significance, and a reduction in dosage in the elderly is not warranted.
No dosage adjustment is necessary in patients with renal insufficiency. In patients with chronic renal
impairment (creatinine clearance ranging from 9.0 to 55 mL/min), the values for AUC, maximum plasmaconcentration, half-life, and protein binding after a single dose of 14C-finasteride were similar to thoseobtained in healthy volunteers. Urinary excretion of metabolites was decreased in patients with renalimpairment. This decrease was associated with an increase in fecal excretion of metabolites. Plasmaconcentrations of metabolites were significantly higher in patients with renal impairment (based on a 60%increase in total radioactivity AUC). Furthermore, finasteride has been well tolerated in men with normalrenal function receiving up to 80 mg/day for 12 weeks where exposure of these patients to metaboliteswould presumably be much greater.
The efficacy of PROPECIA was demonstrated in men (88% Caucasian) with mild to moderate
androgenetic alopecia (male pattern hair loss) between 18 and 41 years of age. In order to preventseborrheic dermatitis which might confound the assessment of hair growth in these studies (controlledphase and extensions), all men, whether treated with finasteride or placebo, were instructed to use aspecified, medicated, tar-based shampoo (Neutrogena T/Gel®** Shampoo).
** Registered trademark of Johnson & Johnson
There were three double-blind, randomized, placebo-controlled studies of 12-month duration. The two
primary endpoints were hair count and patient self-assessment; the two secondary endpoints wereinvestigator assessment and ratings of photographs. The three studies were conducted in 1,879 men withmild to moderate, but not complete, hair loss. Two of the studies enrolled men with predominantly mild tomoderate vertex hair loss (n=1,553). The third enrolled men having mild to moderate hair loss in theanterior mid-scalp area with or without vertex balding (n=326).
Two studies on Vertex Baldness
Of the men who completed the first 12 months of the two vertex baldness trials, 1,215 elected to
continue in double-blind, placebo-controlled, 12-month extension studies. There were 547 men receivingPROPECIA for both the initial and extension periods (up to 24 months) and 60 men receiving placebo forthe same periods. In addition, there were 65 men who received PROPECIA for the initial 12 monthsfollowed by placebo in the 12-month extension period, and 543 men who received placebo for the initial 12months followed by PROPECIA in the 12-month extension period (See Figure below).
Hair counts were assessed by photographic enlargements of a representative area of active hair loss.
In these two studies in men with vertex baldness, significant increases in hair count were demonstrated at6 and 12 months in men treated with PROPECIA, while significant hair loss from baseline wasdemonstrated in those treated with placebo. At 12 months there was a 107-hair difference from placebo(p<0.001, PROPECIA [n=679 evaluable men] vs placebo [n=672 evaluable men]) within a 1-inch diametercircle (5.1 cm2). Hair count was maintained in those men taking PROPECIA (n=433 evaluable men) for upto 24 months, while the placebo group (n=47 evaluable men) continued to show progressive hair loss. At24 months, this resulted in a 138-hair difference between treatment groups (p<0.001) within the samearea. Patients who switched from placebo to PROPECIA (n=426 evaluable men) at the end of the initial 12months had an increase in hair count at 24 months. A change of treatment from PROPECIA to placebo(n=48 evaluable men) at the end of the initial 12 months resulted in reversal of the increase in hair count12 months later, at 24 months. See figure below for combined study results.
At 12 months, 14% of men treated with PROPECIA had hair loss (defined as any decrease in hair
count from baseline) compared with 58% of men in the placebo group. In men treated for up to 24months, 17% of those treated with PROPECIA demonstrated hair loss compared with 72% of those in theplacebo group.
Effect on Hair Count†
Number of Hairs in a 1-Inch Diameter Circle
† Pooled data from vertex hair loss studies (mean baseline hair count = 876)†† At the end of initial 12-month period, treatment switched from PROPECIA to placebo( PROPECIA/Placebo) or from placebo to PROPECIA ( Placebo/PROPECIA).
Patient self-assessment was obtained at each clinic visit from a self-administered questionnaire, which
included questions on their perception of hair growth, hair loss, and appearance. This self-assessmentdemonstrated an increase in amount of hair, a decrease in hair loss, and improvement in appearance inmen treated with PROPECIA. Overall improvement compared with placebo was seen as early as 3months (p<0.05), with continued improvement over 24 months.
Investigator assessment was based on a 7-point scale evaluating increases or decreases in scalp hair
at each patient visit. This assessment showed significantly greater increases in hair growth in men treated
with PROPECIA compared with placebo as early as 3 months (p<0.001). At 12 months, the investigatorsrated 65% of men treated with PROPECIA as having increased hair growth compared with 37% in theplacebo group. At 24 months, the investigators rated 80% of men treated with PROPECIA as havingincreased hair growth compared with 47% of men treated with placebo.
Standardized photographs of the head were assessed in a blinded fashion, at the beginning of the
study and at 6, 12, 18 and 24 months. An independent panel rated increases or decreases in scalp hair onthe same 7-point scale as the investigator assessment. At 12 months, 48% of men treated withPROPECIA had an increase as compared with 7% of men treated with placebo. At 24 months, anincrease in hair growth was demonstrated in 66% of men treated with PROPECIA compared with 7% ofmen treated with placebo. Based on this assessment, continued treatment with PROPECIA resulted infurther improvement. These results were observed in the context of no further increase in hair countbetween month 12 and month 24.
In one of the two vertex baldness studies, patients were questioned on non-scalp body hair growth.
PROPECIA did not appear to affect non-scalp body hair.
Study on Hair Loss in the Anterior Mid-Scalp Area
A third study of 12-month duration, designed to assess the efficacy of PROPECIA in men with hair loss
in the anterior mid-scalp area, also demonstrated significant increases in hair count compared withplacebo. Increases in hair count were accompanied by improvements in patient self-assessment,investigator assessment, and ratings based on standardized photographs. Hair counts were obtained inthe anterior mid-scalp area, and did not include the area of bitemporal recession or the anterior hairline.
Summary of Clinical Studies
Clinical studies were conducted in men aged 18 to 41 with mild to moderate degrees of androgenetic
alopecia. All men treated with PROPECIA or placebo received a tar-based shampoo(Neutrogena T/Gel®** Shampoo). Clinical improvement was seen as early as 3 months in the patientstreated with PROPECIA and led to a net increase in scalp hair count and hair regrowth. In addition, clinicalstudies demonstrated slowing of hair loss with PROPECIA by patient self-assessment. These effects weremaintained through the second year of treatment. Maintenance of or improvement in clinical efficacy hasalso been demonstrated in controlled and open-extension studies for up to 3 years.
Ethnic Analysis of Clinical Data
In a combined analysis of the two studies on vertex baldness, mean hair count changes from baseline
were 91 vs –19 hairs (PROPECIA vs placebo) among Caucasians (n=1,185), 49 vs –27 hairs amongBlacks (n=84), 53 vs –38 hairs among Asians (n=17), 67 vs 5 hairs among Hispanics (n=45) and67 vs -15 hairs among other ethnic groups (n=20). Patient self-assessment showed improvement acrossracial groups with PROPECIA treatment, except for satisfaction of the frontal hairline and vertex in Blackmen, who were satisfied overall.
A sexual function questionnaire was self-administered by patients participating in the two vertex
baldness trials to detect more subtle changes in sexual function. At Month 12, statistically significantdifferences in favor of placebo were found in 3 of 4 domains (sexual interest, erections, and perception ofsexual problems). However, no significant difference was seen in the question on overall satisfaction withsex life.
INDICATIONS AND USAGE
PROPECIA is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN
. Safety and efficacy were demonstrated in men between 18 to 41 years of age with mild to
moderate hair loss of the vertex and anterior mid-scalp area (See CLINICAL PHARMACOLOGY, Clinical
Efficacy in bitemporal recession has not been established.
PROPECIA is not indicated in women (see CONTRAINDICATIONS).
PROPECIA is not indicated in children (see PRECAUTIONS, Pediatric Use).
PROPECIA is contraindicated in the following:Pregnancy. Finasteride use is contraindicated in women when they are or may potentially be pregnant.
Because of the ability of 5α-reductase inhibitors to inhibit the conversion of testosterone to DHT,finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman whoreceives finasteride. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug,the pregnant woman should be apprised of the potential hazard to the male fetus. (See also WARNINGS,
EXPOSURE OF WOMEN - RISK TO MALE FETUS; and PRECAUTIONS, Information for Patients andPregnancy.) In female rats, low doses of finasteride administered during pregnancy have producedabnormalities of the external genitalia in male offspring.
Hypersensitivity to any component of this medication.
PROPECIA is not indicated for use in pediatric patients (See INDICATIONS AND USAGE; and
PRECAUTIONS, Pediatric Use) or women (See also PRECAUTIONS, Information for Patients andPregnancy; and HOW SUPPLIED, Storage and Handling).
EXPOSURE OF WOMEN - RISK TO MALE FETUS
Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may
potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potentialrisk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active ingredientduring normal handling, provided that the tablets have not been broken or crushed. (See alsoCONTRAINDICATIONS; PRECAUTIONS, Information for Patients and Pregnancy; and HOW SUPPLIED,Storage and Handling.)
Caution should be used in the administration of PROPECIA in patients with liver function abnormalities,
as finasteride is metabolized extensively in the liver.
Information for Patients
Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may
potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potentialrisk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active ingredientduring normal handling, provided that the tablets have not been broken or crushed. (See alsoCONTRAINDICATIONS; WARNINGS, EXPOSURE OF WOMEN - RISK TO MALE FETUS;PRECAUTIONS, Pregnancy; and HOW SUPPLIED, Storage and Handling.)See also Patient Package Insert.
Drug/Laboratory Test Interactions
In clinical studies with PROPECIA in men 18-41 years of age, the mean value of serum prostate-
specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12. When finasterideis used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased byapproximately 50%. Until further information is gathered in men >41 years of age without BPH,consideration should be given to doubling the PSA level in men undergoing this test while takingPROPECIA.
No drug interactions of clinical importance have been identified. Finasteride does not appear to affect
the cytochrome P450-linked drug metabolizing enzyme system. Compounds that have been tested in maninclude antipyrine, digoxin, propranolol, theophylline, and warfarin and no interactions were found.
Other concomitant therapy: Although specific interaction studies were not performed, finasteride doses
of 1 mg or more were concomitantly used in clinical studies with acetaminophen, α-blockers, analgesics,angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors,prostaglandin synthetase inhibitors (NSAIDs), and quinolone anti-infectives without evidence of clinicallysignificant adverse interactions.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No evidence of a tumorigenic effect was observed in a 24-month study in Sprague-Dawley rats
receiving doses of finasteride up to 160 mg/kg/day in males and 320 mg/kg/day in females. These dosesproduced respective systemic exposure in rats of 888 and 2,192 times those observed in man receivingthe recommended human dose of 1 mg/day. All exposure calculations were based on calculatedAUC(0-24 hr) for animals and mean AUC(0-24 hr) for man (0.05 µg•hr/mL).
In a 19-month carcinogenicity study in CD-1 mice, a statistically significant (p≤0.05) increase in the
incidence of testicular Leydig cell adenomas was observed at a dose of 250 mg/kg/day (1,824 times thehuman exposure). In mice at a dose of 25 mg/kg/day (184 times the human exposure, estimated) and inrats at a dose of ≥40 mg/kg/day (312 times the human exposure) an increase in the incidence of Leydigcell hyperplasia was observed. A positive correlation between the proliferative changes in the Leydig cells
and an increase in serum LH levels (2-3 fold above control) has been demonstrated in both rodentspecies treated with high doses of finasteride. No drug-related Leydig cell changes were seen in eitherrats or dogs treated with finasteride for 1 year at doses of 20 mg/kg/day and 45 mg/kg/day (240 and 2,800times, respectively, the human exposure) or in mice treated for 19 months at a dose of 2.5 mg/kg/day(18.4 times the human exposure).
No evidence of mutagenicity was observed in an in vitro bacterial mutagenesis assay, a mammalian
cell mutagenesis assay, or in an in vitro alkaline elution assay. In an in vitro chromosome aberrationassay, when Chinese hamster ovary cells were treated with high concentrations (450-550 µmol) offinasteride, there was a slight increase in chromosome aberrations. These concentrations correspond to18,000-22,000 times the peak plasma levels in man given a total dose of 1 mg. Further, theconcentrations (450-550 µmol) used in in vitro studies are not achievable in a biological system. In anin vivo chromosome aberration assay in mice, no treatment-related increase in chromosome aberrationwas observed with finasteride at the maximum tolerated dose of 250 mg/kg/day (1,824 times the humanexposure, estimated) as determined in the carcinogenicity studies.
In sexually mature male rabbits treated with finasteride at 80 mg/kg/day (4,344 times the estimated
human exposure) for up to 12 weeks, no effect on fertility, sperm count, or ejaculate volume was seen. Insexually mature male rats treated with 80 mg/kg/day of finasteride (488 times the estimated humanexposure), there were no significant effects on fertility after 6 or 12 weeks of treatment; however, whentreatment was continued for up to 24 or 30 weeks, there was an apparent decrease in fertility, fecundity,and an associated significant decrease in the weights of the seminal vesicles and prostate. All theseeffects were reversible within 6 weeks of discontinuation of treatment. No drug-related effect on testes oron mating performance has been seen in rats or rabbits. This decrease in fertility in finasteride-treated ratsis secondary to its effect on accessory sex organs (prostate and seminal vesicles) resulting in failure toform a seminal plug. The seminal plug is essential for normal fertility in rats but is not relevant in man.
PregnancyTeratogenic Effects: Pregnancy Category X
PROPECIA is not indicated for use in women.
Administration of finasteride to pregnant rats at doses ranging from 100 µg/kg/day to 100 mg/kg/day
(5-5,000 times the recommended human dose of 1 mg/day) resulted in dose-dependent development ofhypospadias in 3.6 to 100% of male offspring. Pregnant rats produced male offspring with decreasedprostatic and seminal vesicular weights, delayed preputial separation, and transient nipple developmentwhen given finasteride at ≥30 µg/kg/day (≥ 1.5 times the recommended human dose of 1 mg/day) anddecreased anogenital distance when given finasteride at ≥3 µg/kg/day (one-fifth the recommended humandose of 1 mg/day). The critical period during which these effects can be induced in male rats has beendefined to be days 16-17 of gestation. The changes described above are expected pharmacologicaleffects of drugs belonging to the class of Type II 5α-reductase inhibitors and are similar to those reportedin male infants with a genetic deficiency of Type II 5α-reductase. No abnormalities were observed infemale offspring exposed to any dose of finasteride in utero.
No developmental abnormalities have been observed in first filial generation (F1) male or female
offspring resulting from mating finasteride-treated male rats (80 mg/kg/day; 488 times the humanexposure) with untreated females. Administration of finasteride at 3 mg/kg/day (150 times therecommended human dose of 1 mg/day) during the late gestation and lactation period resulted in slightlydecreased fertility in F1 male offspring. No effects were seen in female offspring. No evidence ofmalformations has been observed in rabbit fetuses exposed to finasteride in utero from days 6-18 ofgestation at doses up to 100 mg/kg/day (5000 times the recommended human dose of 1 mg/day).
However, effects on male genitalia would not be expected since the rabbits were not exposed during thecritical period of genital system development.
The in utero effects of finasteride exposure during the period of embryonic and fetal development were
evaluated in the rhesus monkey (gestation days 20-100), a species more predictive of humandevelopment than rats or rabbits. Intravenous administration of finasteride to pregnant monkeys at dosesas high as 800 ng/day (at least 750 times the highest estimated exposure of pregnant women tofinasteride from semen of men taking 1 mg/day) resulted in no abnormalities in male fetuses. Inconfirmation of the relevance of the rhesus model for human fetal development, oral administration of avery high dose of finasteride (2 mg/kg/day; 100 times the recommended human dose of 1 mg/day orapproximately 12 million times the highest estimated exposure to finasteride from semen of men taking1 mg/day) to pregnant monkeys resulted in external genital abnormalities in male fetuses. No other
abnormalities were observed in male fetuses and no finasteride-related abnormalities were observed infemale fetuses at any dose.
PROPECIA is not indicated for use in women.
It is not known whether finasteride is excreted in human milk.
PROPECIA is not indicated for use in pediatric patients.
Safety and effectiveness in pediatric patients have not been established.
Clinical efficacy studies with PROPECIA did not include subjects aged 65 and over. Based on
pharmacokinetics, no dosage adjustment is necessary in the elderly (see CLINICAL PHARMACOLOGY,Pharmacokinetics).
Clinical Studies for PROPECIA (finasteride 1 mg) in the Treatment of Male Pattern Hair Loss
In controlled clinical trials for PROPECIA of 12-month duration, 1.4% of the patients were discontinued
due to adverse experiences that were considered to be possibly, probably or definitely drug-related (1.6%for placebo); 1.2% of patients on PROPECIA and 0.9% of patients on placebo discontinued therapybecause of a drug-related sexual adverse experience. The following clinical adverse reactions werereported as possibly, probably or definitely drug-related in ≥1% of patients treated for 12 months withPROPECIA or placebo, respectively: decreased libido (1.8%, 1.3%), erectile dysfunction (1.3%, 0.7%) andejaculation disorder (1.2%, 0.7%; primarily decreased volume of ejaculate: [0.8%, 0.4%]). Integratedanalysis of clinical adverse experiences showed that during treatment with PROPECIA, 36 (3.8%) of 945men had reported one or more of these adverse experiences as compared to 20 (2.1%) of 934 mentreated with placebo (p=0.04). Resolution occurred in all men who discontinued therapy with PROPECIAdue to these side effects and in 58% of those who continued therapy.
In a study of finasteride 1 mg daily in healthy men, a median decrease in ejaculate volume of 0.3 mL
(-11%) compared with 0.2 mL (–8%) for placebo was observed after 48 weeks of treatment. Two otherstudies showed that finasteride at 5 times the dosage of PROPECIA (5 mg daily) produced significantmedian decreases of approximately 0.5 mL (-25%) compared to placebo in ejaculate volume but this wasreversible after discontinuation of treatment.
In the clinical studies with PROPECIA, the incidences for breast tenderness and enlargement,
hypersensitivity reactions, and testicular pain in finasteride-treated patients were not different from those inpatients treated with placebo.
Postmarketing Experience for PROPECIA (finasteride 1 mg)
Breast tenderness and enlargement; hypersensitivity reactions including rash, pruritus, urticaria, and
swelling of the lips and face; and testicular pain.
Controlled Clinical Trials and Long-Term Open Extension Studies for PROSCAR* (finasteride 5 mg) in theTreatment of Benign Prostatic Hyperplasia
In controlled clinical trials for PROSCAR of 12-month duration, 1.3% of the patients were discontinued
due to adverse experiences that were considered to be possibly, probably or definitely drug-related (0.9%for placebo); only one patient on PROSCAR (0.2%) and one patient on placebo (0.2%) discontinuedtherapy because of a drug-related sexual adverse experience. The following clinical adverse reactionswere reported as possibly, probably or definitely drug-related in ≥1% of patients treated for 12 months withPROSCAR or placebo, respectively: erectile dysfunction (3.7%, 1.1%), decreased libido (3.3%, 1.6%) anddecreased volume of ejaculate (2.8%, 0.9%). The adverse experience profiles for patients treated withfinasteride 1 mg/day for 12 months and those maintained on PROSCAR for 24 to 48 months were similarto that observed in the 12-month controlled studies with PROSCAR. Sexual adverse experiences resolvedwith continued treatment in over 60% of patients who reported them.
In clinical studies, single doses of finasteride up to 400 mg and multiple doses of finasteride up to
80 mg/day for three months did not result in adverse reactions. Until further experience is obtained, nospecific treatment for an overdose with finasteride can be recommended.
Significant lethality was observed in male and female mice at single oral doses of 1,500 mg/m2
(500 mg/kg) and in female and male rats at single oral doses of 2,360 mg/m2 (400 mg/kg) and5,900 mg/m2 (1,000 mg/kg), respectively.
DOSAGE AND ADMINISTRATION
The recommended dosage is 1 mg once a day.
PROPECIA may be administered with or without meals.
In general, daily use for three months or more is necessary before benefit is observed. Continued use
is recommended to sustain benefit. Withdrawal of treatment leads to reversal of effect within 12 months.
No. 6550 — PROPECIA tablets, 1 mg, are tan, octagonal, film-coated convex tablets with code MRK
71 on one side and PROPECIA 1 on the other. They are supplied as follows:
0006-0071-31 unit of use bottles of 30
0006-0071-61 PROPAK®*** - carton of 3 unit of use bottles of 30.
Store at room temperature, 15-30°C (59-86°F). Keep container closed and protect from moisture.
Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may
potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potentialrisk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active ingredientduring normal handling, provided that the tablets are not broken or crushed. (See WARNINGS,EXPOSURE OF WOMEN - RISK TO MALE FETUS; and PRECAUTIONS, Information for Patients andPregnancy.)
*** Registered trademark of MERCK & CO., INC.
GATES CACTUS & SUCCULENT SOCIETY Cactaceae Azetekium, Epithelantha, Geohintonia, Pelecyphora Ferocactus, Hamatocactus, Leuchtenbergia Eriosyce,under 5” (incl. Neoporteria, Neochilenea) Eriosyce, over 5” (incl. Neoporteria, Neochilenea) Parodia- hooked spines (incl. Notocactus) Parodia- w/o hooked spines (incl. Notocactus) Collections, 5 to 12 plants (triple points) CRASSU
Failure to handle more than one internal representation in visual detection tasks Andrei Gorea*† and Dov Sagi‡ *Laboratoire de Psychologie Expe´rimentale, Centre National de la Recherche Scientifique & Rene´ Descartes University, 71 Ave. Edouard Vaillant, 92774Boulogne-Billancourt, France; and ‡Department of Neurobiology͞Brain Research, Weizmann Institute of Science, Rehovot, 76100